舒利迭改善COPD合并尘肺病患者肺功能研究

目的研究舒利迭对COPD合并尘肺病患者肺功能影响的机制。方法选择我院肺功能Ⅱ～Ⅲ组稳定期COPD合并尘肺病和COPD患者各28例,给予舒利迭吸入治疗4周,检测治疗前后两组FEV1、FVC、FEV1%和FEV1/FVC等指标,比较两组肺功能改善程度。结果两组治疗后FEV1、FVC、FEV1%和FEV1/FVC均较治疗前显著提高(P<0.05)。治疗后COPD合并尘肺病组的FEV1%低于COPD组(P<0.05);两组FEV1/FVC差异无显著性(P>0.05)。结论舒利迭吸入治疗能显著改善COPD患者和COPD合并尘肺患者的肺功能,但合并尘肺病使舒利迭对COPD患者的疗效减弱。

Study of the Seretide anapnotherapy in treatment of chronic obstructive pulmonary disease patients complicated with pneumoconiosis

Objective To study the mechanism of Seretide anapnotherapy in treatment of moderate-to-severe chronic obstructive pulmonary disease complicated with pneumoconiosis.Methods 28 patients with COPD and 28 patients with COPD and pneumoconiosis were recruited from outpatient departments in our hospital.They were treated with Seretide for 4 weeks.The forced expiratory volume in 1s(FEV1),forced vital capacity(FVC),percentage of FEV1 and predict value(FEV1%) and FEV1/FVC were measured after 4 weeks treatment.Results Seretide treatment produced a significant improvement in FEV1,FVC,FEV1% and FEV1/FVC among all patients.Compared with the COPD patients,COPD patients with pneumoconiosis had a lower increase in FEV1% after treatment;but the FEV1/FVC was not significantly different between two groups.Conclusions Seretide anapnotherapy can improve the pulmonary function in both COPD patients and COPD patients with pneumoconiosis.Pneumoconiosis impairs the effectiveness of Seretide in COPD patients.